Plain-English translation of NCT06245746 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called UCMSC-Exo, which is made from tiny particles derived from umbilical cord stem cells. The goal is to see if this medication can help patients with acute myeloid leukemia recover their blood cell counts more quickly after receiving chemotherapy. The treatment is given as an intravenous infusion (through a vein), and you would be monitored for up to one year.
Chemotherapy for leukemia is lifesaving, but it can severely damage the bone marrow's ability to make new blood cells, leading to serious infections, bleeding, and organ damage. Doctors need better ways to help the bone marrow recover faster so patients can tolerate their full treatment and avoid life-threatening complications.
You likely qualify if…
You likely don't qualify if…
You would receive a single intravenous infusion of the medication at one of three escalating dose levels. After the infusion, you would come back for follow-up visits to have blood tests and check-ups over the course of one year. The study is small—only 9 patients total—so researchers can carefully monitor your safety and how well the treatment helps your blood cells recover.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Enrollment target
~9 participants
Started
February 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qiubai Li, Professor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.